Normal versus tumor biomarkers LN negative versus LN positive biomarkers SLC39A5, C3orf32, TP73, CD1B, LAT2, TTC13, ARV1, NMT1, PCDHGA4, PCDHGA11, PCDHGA9, DCAKD, GJA1, OR7A17, LOX, PCDHGA1, PCDHGB1, PCDHGB6, KRT19, ZNF655, KRTAP4-4,
PCDHGA12, PCDHGB3, PCDHGB7, TAAR5, SEMA3E, HOXD1 PCDHGA6, PCDHGA8, PCDHGA10, PCDHGA5, PCDHGB4, PCDHGA3, PCDHGA2, PCDHGB2, PCDHGA7, PCDHGB5, C20orf197, SLC16A5, FUT8, SLC15A2, C17orf93, PRAC, OCLN, TMEM144, FGF2, PDX1, CCL1, LILRB5, LCE3D, GPR45, LPO, CGB5
All CDH genes (n = 27) screened in this study include CDH1 (E-cadherin), CDH2 (N-cadherin), CDH3 (P-cadherin), CDH4 (R-cadherin), CDH5 (VE-cadherin), CDH6 (K-cadherin), CDH7 (cadherin 7), CDH8 (cadherin 8), CDH9 (T1-cadherin), CDH10 (T2-cadherin), CDH11 (OB-cadherin), CDH12 (N-cadherin 2), CDH13 (H-cadherin), CDH15 (M-cadherin), CDH16 (KSP-cadherin), CDH17 (LI-cadherin), CDH18 (cadherin 18), CDH20 (cadherin 20),
PCDHGA12 (CDH21), CDH22 CDH23 CDH24 DCHS1 (CDH19, or CDH25), CDH26 DCHS2 (CDH27), CDHR3 (CDH28), and CDHR4 (CDH29).